T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 3 399.45 INR -0.61%
Market Cap: 1.2T INR
Have any thoughts about
Torrent Pharmaceuticals Ltd?
Write Note

Torrent Pharmaceuticals Ltd
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Torrent Pharmaceuticals Ltd
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Operating Expenses
-â‚ą56.9B
CAGR 3-Years
-12%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Operating Expenses
-â‚ą146.4B
CAGR 3-Years
-13%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Operating Expenses
-â‚ą121.4B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
-9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Operating Expenses
-â‚ą285.7B
CAGR 3-Years
-14%
CAGR 5-Years
-10%
CAGR 10-Years
-11%
Lupin Ltd
NSE:LUPIN
Operating Expenses
-â‚ą113B
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
M
Mankind Pharma Ltd
NSE:MANKIND
Operating Expenses
-â‚ą47.9B
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Torrent Pharmaceuticals Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

In the bustling realm of Indian pharmaceuticals, Torrent Pharmaceuticals Ltd. has carved out a notable niche, emerging from the industrious land of Gujarat. Founded in 1959, this company has transformed from a modest player to a major force in the industry, traversing the complexities of pharmaceutical manufacturing and global distribution. At its core, Torrent Pharmaceuticals is driven by a commitment to healthcare innovation and therapeutic excellence. The company systematically engages in developing, manufacturing, and marketing a wide array of generic pharmaceutical products primarily targeting cardiovascular, central nervous system, gastro-intestinal, anti-infective, and anti-diabetic therapeutic categories. This diverse product portfolio positions Torrent not just as a provider of remedies but as a critical player in improving health outcomes across numerous demographics and geographies. Torrent Pharmaceuticals operates on a robust business model that effectively integrates research, development, and widespread distribution to generate revenue. The company channels significant resources into its R&D capabilities, perpetually expanding its pipeline to introduce more effective and affordable medications. This ongoing innovation supports their competitive edge while fortifying their catalog of offerings. Additionally, Torrent's strategic alliances and acquisitions—most notably, the key acquisition of Elder Pharmaceuticals' branded domestic formulations business in India—have further catapulted its market presence both domestically and internationally. By leveraging its extensive marketing network and manufacturing capabilities compliant with international standards, Torrent not only bankrolls its growth through product sales but also ensures global reach, cementing its role as a pivotal component of the healthcare landscape.

TORNTPHARM Intrinsic Value
1 989.4 INR
Overvaluation 41%
Intrinsic Value
Price
T

See Also

What is Torrent Pharmaceuticals Ltd's Operating Expenses?
Operating Expenses
-56.9B INR

Based on the financial report for Sep 30, 2024, Torrent Pharmaceuticals Ltd's Operating Expenses amounts to -56.9B INR.

What is Torrent Pharmaceuticals Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-10%

Over the last year, the Operating Expenses growth was -9%. The average annual Operating Expenses growth rates for Torrent Pharmaceuticals Ltd have been -12% over the past three years , -6% over the past five years , and -10% over the past ten years .

Back to Top